GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Debt-to-EBITDA

Betta Pharmaceuticals Co (SZSE:300558) Debt-to-EBITDA : 5.26 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Betta Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥405 Mil. Betta Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥2,082 Mil. Betta Pharmaceuticals Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥473 Mil. Betta Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 5.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Betta Pharmaceuticals Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:300558' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.83   Max: 5.65
Current: 5.65

During the past 13 years, the highest Debt-to-EBITDA Ratio of Betta Pharmaceuticals Co was 5.65. The lowest was 0.01. And the median was 0.83.

SZSE:300558's Debt-to-EBITDA is ranked worse than
83.23% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.695 vs SZSE:300558: 5.65

Betta Pharmaceuticals Co Debt-to-EBITDA Historical Data

The historical data trend for Betta Pharmaceuticals Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Debt-to-EBITDA Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 0.01 0.02 3.29 3.57

Betta Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 4.81 3.72 14.11 5.26

Competitive Comparison of Betta Pharmaceuticals Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's Debt-to-EBITDA falls into.



Betta Pharmaceuticals Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Betta Pharmaceuticals Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(606.124 + 1824.183) / 680.517
=3.57

Betta Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(405.167 + 2081.829) / 472.94
=5.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Betta Pharmaceuticals Co  (SZSE:300558) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Betta Pharmaceuticals Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines